The global Women’s Health Therapeutics Market size is
expected to reach USD 210.9 billion by 2025, according to a new report by Grand
View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the
forecast period. Entry of effective drugs, a rise in awareness about early
diagnosis and treatment, along with prevalence of chronic diseases are among
the key factors likely to drive the market during the forecast period.
The women’s health therapeutics
market is expected to witness high growth in the forthcoming years due to
increasing investment by key market players to fulfill demand in areas of
infection, cancer, and pregnancy-related complications. In October 2016,
Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology
Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing
fertility services and treatment to people with delayed childbirth. Juneau
Biosciences, LLC has deployed USD 35 million until 2017 towards development of
molecular diagnostics and therapeutics for endometriosis (uterus) conditions.
In January 2018, Melinta
Therapeutics, Inc. acquired The Medicines Company’s infectious diseases
business. This acquisition would help to the former expand its portfolio by
offering life-saving treatment options. In November 2017, Biocon launched
KRABEVA, a biosimilar used for the treatment of metastatic colorectal,
cervical, ovarian, and brain cancer.
Increasing investments by top market
players are anticipated to propel the global market over the forecast period.
There is significant unmet need
associated with treatment options for female sexual dysfunction. Currently,
there are no Food and Drug Administration (FDA)-approved drugs for the
treatment of female sexual dysfunction and many promising molecules are in late
stage of development phase. Some of these molecules include LibiGel by BioSante
Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II
of clinical trials respectively in U.S.
Further key findings from the report suggest:
- By type, infection accounted for the largest
market share in 2017 and is expected to maintain its dominance during the
forecast period due to rising drug approvals, availability of diagnostic
tests and treatments, and high incidence of infectious diseases
- Ovarian cancer is anticipated to be the
fastest-growing sub-segment of oncology during the forecast period due to
high prevalence of ovarian cancer and approval of new and improved drugs
- North America is expected to maintain its
dominance in the coming years due to high awareness about women’s health,
increase in number of advanced diagnostic and treatment methods, mergers
and acquisitions by market players, and rise in infections and cancer
cases
- Asia Pacific is likely to witness significant
growth over the next decade due to improving healthcare facilities,
increase in commercialization and approval of products, and investment by
market players
- Some of the key players in women’s health
therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva
Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS)
Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F.
Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and
Sanofi.